Currently out of the existing stock ratings of Jay Olson, 459 are a BUY (91.62%), 41 are a HOLD (8.18%), 1 are a SELL (0.2%).

Jay Olson

Work Performance Price Targets & Ratings Chart

Analyst Jay Olson, currently employed at OPPENHEIMER, carries an average stock price target met ratio of 45.94% that have a potential upside of 43.11% achieved within 179 days.

Jay Olson’s has documented 1,039 price targets and ratings displayed on 69 stocks. The coverage is on Healthcare, Industrials, Financial Services, Utilities sectors.

Most recent stock forecast was given on RVMD, Revolution Medicines at 27-Aug-2026.

Wall Street Analyst Jay Olson

Analyst best performing recommendations are on TERN (TERNS PHARMACEUTICALS).
The best stock recommendation documented was for PRTA (PROTHENA PLC) at 6/1/2021. The price target of $45 was fulfilled within 10 days with a profit of $17.56 (63.99%) receiving and performance score of 63.99.

Average potential price target upside

of $108.53 (80.22%) on MLND (MILLENDO THERAPEUTICS).
of $86.11 (54.35%) on MDGL (MADRIGAL PHARMACEUTICALS).
of $70.9 (114.4%) on PRAX (PRAXIS PRECISION MEDICINES ).

ACAD ACADIA Pharmaceuticals AMGN Amgen BCYC Bicycle Therapeutics Ltd BIIB Biogen CBAY Cymabay Therapeu CRSP Crispr Therapeutics AG EDIT Editas Medicine FREQ Frequency Therapeutics ICPT Intercept Pharmaceuticals MRTX Mirati Ther NBIX Neurocrine Biosciences NTLA Intellia Therapeutics PRTA Prothena plc PTLA Portola Pharmaceuticals SAGE Sage Therapeutic SGEN Seagen SRRA Sierra Oncology TXMD TherapeuticsMD ENTA Enanta Pharmaceuticals AXON Axon Enterprise AYLA Ayala Pharmaceuticals DNLI Denali Therapeutics ETN Eaton PLC EXEL Exelixis FOCS Focus Financial Partners INCY yte JSPR Jasper Therapeutics KRTX Karuna Therapeutics MDGL Madrigal Pharmaceuticals NKTR Nektar Therapeutics BIVI Biovie CINC CinCor Pharma ETNB 89bio CGTX Cognition Therapeutics MDCO The Medicines Company RLMD Relmada Therapeutics RVMD Revolution Medicines VKTX Viking Therapeutics VYGR Voyager Therapeutics MRNS Marinus Pharmaceuticals GLTO Galecto INO Inovio Pharmaceuticals IONS Ionis Pharmaceuticals STRO Sutro Biopharma TERN Terns Pharmaceuticals QTTB Q32 Bio CNAT Conatus Pharmaceuticals INDP Indaptus Therapeutics MDWD Mediwound Ltd MNKD MannKind Corp NTEC Intec Pharma Ltd IMRX Immuneering Corp DYN Dyne Therapeutics PRAX Praxis Precision Medicines ATAI ATAI Life Sciences BV AXSM Axsome Therapeutics CB Chubb Ltd CI Cigna Corp FR First Industrial Realty Trust KRT Karat Packaging MLND Millendo Therapeutics OVID Ovid Therapeutics SA Seabridge Gold SR Spire VRTX Vertex Pharmaceuticals SKYE Skye Bioscience, Common Stock GANX Gain Therapeutics PASG Passage Bio SGMT Sagimet Biosciences Series A Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Ananda Ghosh (HC WAINWRIGHT)

Buy Since 14-Dec-2025

$33

$12.32 (59.57%)

$37

Please subscribe to see extended stock data

Evan Seigerman (BMO)

Buy Since 16-Apr-2025

$34

$13.32 (64.41%)

$36

Please subscribe to see extended stock data

Jason Butler (JMP)

Buy Since 25-Nov-2019

$33

$12.32 (59.57%)

$36

Please subscribe to see extended stock data

David Hoang (DEUTSCHE BANK)

Buy Since 24-Sep-2025

$31

$10.32 (49.90%)

$38

Please subscribe to see extended stock data

Ami Fadia (NEEDHAM)

Buy Since 27-Feb-2024

$35

$14.32 (69.25%)

$41

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Jay Olson most bullish on?

Potential upside of $369.22 has been obtained for PRAX (PRAXIS PRECISION MEDICINES )

Which stock is Jay Olson most reserved on?

Potential downside of -$33.89 has been obtained for INCY (YTE)

What Year was the first public recommendation made by Jay Olson?

On 2015